Publications & Posters

KemPharm^® believes that its LAT^® Platform technology offers potential benefits to improve drug properties by developing prodrugs that are new molecules with improved attributes over FDA-approved drugs, such as enhanced bioavailability, extended duration of action, increased safety, and reduced susceptibility to abuse.

Publications

Drug Development & Delivery – March 2019

“Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs”

Pain Medicine – October 28, 2017

“Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users”

Pain Medicine – August 25, 2017

“Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen Compared with Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers”

Pharmacoepidemiology & Drug Safety – August 3, 2017

“Patterns of abuse and routes of administration for immediate-release hydrocodone combination products”

Poster Presentations

The American Professional Society of ADHD and Related Disorders – January 18-20, 2019

“Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD”

“Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate”

“Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin® XR and Phentermine in Recreational Stimulant Abusers”

“Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers”

American College of Neuropsychopharmacology – December 9-13, 2018

“Assessment of the Intravenous Abuse Potential Of Serdexmethylphenidate (SDX), a Novel, Investigational Prodrug of D-Methylphenidate: Evidence from Nonclinical and Clinical Studies”

American Academy of Child & Adolescent Psychiatry – October 22-27, 2018

“Human Abuse Potential of Intravenous Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers”

“Dose-finding Study of Abuse-Related Effects of Intranasal d-Methylphenidate in Recreational Stimulant Abusers”

American Professional Society for ADHD and Related Disorders – January 12-14, 2018

“Single- and Multiple-dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers ”

2017 International Conference on Opioids (ICOO) – June 11-3, 2016

“Pharmacokinetics and Abuse Potential of KP511, a Novel Prodrug of Hydromorphone, after Intranasal Administration in Recreation Drug Users”

American Academy of Pain Medicine (AAPM) Annual Meeting – March 15-19, 2017

“Oral pharmacokinetics of KP511, a prodrug of hydromorphone, relative to hydromorphone in human volunteers”

“Pharmacokinetics and Abuse Potential of Benzhydrocodone, A Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users”

2016 International Conference on Opioids (ICOO) – June 5-7, 2016

“Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users”

“Relative Bioavailability, Intranasal Abuse Potential, and Safety of Benzhydrocodone/Acetaminophen, a Novel Immediate-Release Hydrocodone Prodrug Combination, Compared With Hydrocodone Bitartrate/Acetaminophen in Recreational Drug Abusers”